贝伐珠单抗维持治疗对比无维持治疗在转移性结直肠癌无化疗间期的随机III期试验(PRODIGE 9)
PRODIGE 9研究为开放标签III期随机对照试验,纳入491例转移性结直肠癌患者,在诱导化疗(12周期氟尿嘧啶+亚叶酸钙+伊立替康+贝伐珠单抗)后无化疗间期比较贝伐珠单抗维持治疗与观察。结果显示两组中位肿瘤控制时间均为15个月,中位无进展生存期分别为9.2和8.9个月,中位总生存期分别为21.7和22.0个月,贝伐珠单抗维持单药未改善肿瘤控制时间、无化疗间期时长、无进展生存期或总生存期。
要点
- 贝伐珠单抗维持治疗未延长无化疗间期或肿瘤控制时间。
- 维持组与观察组的中位无进展生存期和总生存期无显著差异。
- 女性、WHO体能状态评分≥2、原发肿瘤未切除与更短肿瘤控制时间相关。
核心结论
- 贝伐珠单抗维持单药治疗未改善转移性结直肠癌患者的肿瘤控制时间、无化疗间期时长、无进展生存期或总生存期。
研究设计与样本
- 开放标签、III期随机对照试验,纳入491例转移性结直肠癌患者,诱导化疗为12周期氟尿嘧啶+亚叶酸钙+伊立替康+贝伐珠单抗,随后无化疗间期随机接受贝伐珠单抗维持或无治疗观察,疾病进展后重复诱导方案8周期并再次进入无化疗间期。
主要发现
- 诱导化疗期间85例(17%)出现疾病进展或死亡,261例(53%)至少接受一次再诱导,107例(22%)接受两次再诱导,56例(11%)接受三次或以上再诱导。
- 维持组和观察组的中位肿瘤控制时间均为15个月;从随机分组起中位无进展生存期分别为9.2个月和8.9个月;中位总生存期分别为21.7个月和22.0个月。
- 符合方案人群(首次进展后至少接受一次再诱导)中,两组首次无化疗间期中位时长均为4.3个月;中位肿瘤控制时间分别为17.8个月和23.3个月(P = .339),中位无进展生存期分别为9.9个月和9.5个月,中位总生存期分别为27.6个月和28.5个月。
- 多因素分析显示女性、WHO体能状态评分≥2、原发肿瘤未切除与更短的肿瘤控制时间相关。
关键数值与推荐
- 中位肿瘤控制时间在维持组和观察组均为15个月。
- 从随机分组起中位无进展生存期在维持组和观察组分别为9.2个月和8.9个月。
- 中位总生存期在维持组和观察组分别为21.7个月和22.0个月。
- 符合方案人群中位肿瘤控制时间在维持组和观察组分别为17.8个月和23.3个月(P = .339)。
- 符合方案人群中位总生存期在维持组和观察组分别为27.6个月和28.5个月。
临床怎么用
- 转移性结直肠癌诱导化疗后的无化疗间期不建议常规使用贝伐珠单抗维持单药治疗。
- 对于女性、WHO体能状态评分≥2或原发肿瘤未切除的患者,应关注更短的肿瘤控制时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Conflicting results are reported for maintenance treatment with bevacizumab during chemotherapy-free intervals (CFI) in metastatic colorectal cancer after induction chemotherapy. Patients and Methods In this open-label, phase III, randomized controlled trial, we compared the tumor control duration (TCD) observed with bevacizumab maintenance and with no treatment (observation) during CFI subsequent to induction chemotherapy with 12 cycles of fluorouracil, leucovorin, and irinotecan plus bevacizumab. After disease progression, the induction regimen was repeated for eight cycles, followed by a new CFI. Results From March 2010 to July 2013, 491 patients were randomly assigned. Disease progression or death occurred during induction chemotherapy in 85 patients (17%); 261 patients (53%) had at least one reinduction, 107 (22%) had two reinductions, and 56 (11%) had three or more reinductions. The median TCD was 15 months in both groups; the median progression-free survival (PFS) from randomization was 9.2 and 8.9 months in the maintenance group and observation groups, respectively. The TCD observed in both groups was higher compared with the TCD hypotheses of the trial. The median overall survival (OS) was 21.7 and 22.0 months in the maintenance and observation groups, respectively. In the per-protocol population, defined as patients with at least one reinduction after the first progression, the median duration of the first CFI was 4.3 months in both arms; the median TCD was 17.8 and 23.3 months ( P = .339), the median PFS was 9.9 and 9.5 months, and the median OS was 27.6 and 28.5 months in the maintenance and observation groups, respectively. Multivariable analysis revealed that female gender, WHO performance status ≥ 2, and unresected primary tumors were associated with a shorter TCD. Conclusion Bevacizumab maintenance monotherapy did not improve TCD, CFI duration, PFS, or OS.
引用
- Aparicio T, Ghiringhelli F, Boige V, et al. Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). J Clin Oncol. 2018. PMID: 29346040. doi:10.1200/JCO.2017.75.2931
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。